<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947852</url>
  </required_header>
  <id_info>
    <org_study_id>CIA293</org_study_id>
    <nct_id>NCT04947852</nct_id>
  </id_info>
  <brief_title>Efficacy of NIV Masks in COPD</brief_title>
  <official_title>Efficacy of NIV Masks in COPD Patients With Chronic Respiratory Failure: A Randomized Controlled Cross Over Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisher and Paykel Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fisher and Paykel Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized controlled pilot study to compare the efficacy and tolerability of a two&#xD;
      different NIV masks on carbon dioxide in participants with stable chronic obstructive&#xD;
      pulmonary disease (COPD) with chronic type II respiratory failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transcutaneous Carbon Dioxide</measure>
    <time_frame>60 minutes</time_frame>
    <description>mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>60 minutes</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minute Ventilation</measure>
    <time_frame>60 minutes</time_frame>
    <description>Litres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>60 minutes</time_frame>
    <description>Beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>60 minutes</time_frame>
    <description>Breaths per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Dyspnoea Score</measure>
    <time_frame>60 Minutes</time_frame>
    <description>1-6 Ranking, with 1 being best and 6 being worst</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Investigation Mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bi Level CPAP Mask</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bi Level CPAP Mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigation Mask</intervention_name>
    <description>Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff</description>
    <arm_group_label>Comparator Mask</arm_group_label>
    <arm_group_label>Investigation Mask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comparator Mask</intervention_name>
    <description>Oronasal bilevel continuous positive airway pressure mask fitted by the investigational staff</description>
    <arm_group_label>Comparator Mask</arm_group_label>
    <arm_group_label>Investigation Mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A doctor's diagnosis of COPD&#xD;
&#xD;
          -  PtCO2 ≥45mmHg on transcutaneous monitor at baseline measure&#xD;
&#xD;
          -  Oxygen saturation measured by pulse oximetry (SpO2) ≥85%&#xD;
&#xD;
          -  Fits the study mask&#xD;
&#xD;
          -  Can tolerate the therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FEV1/FVC ≥70%&#xD;
&#xD;
          -  Body mass index &gt;35&#xD;
&#xD;
          -  Hypercapnia considered to be primarily due to Obesity Hypoventilation syndrome and/or&#xD;
             Obstructive Sleep Apnea&#xD;
&#xD;
          -  Any condition which makes NIV contra-indicated as per BTS guidelines based on clinical&#xD;
             judgement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Semprini</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research Institute of New Zealand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica R Fogarin</last_name>
    <phone>006495740100</phone>
    <phone_ext>7327</phone_ext>
    <email>jessica.fogarin@fphcare.co.nz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Research Institute New Zealand</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Semprini</last_name>
    </contact>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make IPD available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

